Good Numbers
Gross Margin for Q3 FY24 is 56.3% vs 55.9% in Q3 FY23 and 9M FY24 is 57.1% vs 54.8% in 9MFY23
EBITDA Margin for Q3 FY 24 is 35.2% vs 32.0% in Q3 FY23 and 9M FY24 is 35.3 % vs 32.2% in 9MFY23, aided by new product launches across existing and new markets
Basic EPS increased by 22.2% to Rs.44.19 in 9M FY24 compared to Rs.36.17 in 9M FY23
Cash Flow from Operations in 9MFY24 is ₹189 Crores
Free Cash Flow is ₹72 Crores after Capex investment of ₹117 Crores
Geographical revenues: Latin America and the Rest of the World 83%, US 17%
Caplin Steriles Ltd (“CSL”) 9M FY24 Operating Revenue of ₹210 Crores, a 40.3% Y-o-Y growth
CSL’s revenue composition demonstrates a balanced mix of Product Supply and Milestone + Profit
Share, with the split for 9M FY24 is in the range of 75% and 25% respectivelyReceivable days are at 107 days
As of 31st Dec 2023, Inventories (including in-transit inventory) are at ₹374 Crores and Cash and
Cash equivalents are at ₹832 Crores
Subscribe To Our Free Newsletter |